Literature DB >> 7680437

Prostacyclin-dependent cyclic AMP formation in endothelial cells.

H Schröder1, K Schrör.   

Abstract

The effect of the stable prostacyclin (PGI2) mimetic iloprost on cyclic AMP levels was investigated in cultured porcine aortic endothelial cells. Iloprost (10(-10)-10(-5) mol/l) did not change cyclic AMP levels at passage 1 when endothelial cells were untreated but did so after inhibition of endogenous PGI2 formation by 48 or 72 h treatment with indomethacin or diclofenac (10(-5) mol/l). Iloprost increased cyclic AMP in a concentration-dependent manner and up to 6-fold above control when cells from passage 6 were used. In these cells, basal PGI2 generation was reduced to 20% of that at passage 1. Cyclic AMP stimulation by iloprost (10(-5) mol/l) in passage 6 cells was enhanced, reaching up to 11-fold the control level, when cells were cultured for 48 h in the presence of indomethacin or diclofenac (10(-5) mol/l). Cyclic AMP formation in LLC-PK1 cells, a kidney epithelial cell line without endogenous PGI2 biosynthesis, was markedly (25-fold above basal) stimulated by iloprost and unchanged by pretreatment with indomethacin and diclofenac. The data demonstrate that a continuous basal PGI2 generation occurs in porcine aortic endothelial cells that may be sufficient to completely desensitize PGI2-dependent adenylate cyclase activation, presumably at the receptor or GTP-binding protein level.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7680437     DOI: 10.1007/bf00168779

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  20 in total

1.  Desensitization of iloprost responsiveness in human platelets follows prolonged exposure to iloprost in vitro.

Authors:  U Alt; P J Leigh; A J Wilkins; P K Morris; J MacDermot
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

2.  Rat atrial natriuretic peptide elevates the level of cyclic GMP in astroglia-rich brain cell cultures.

Authors:  A Friedl; C Harmening; B Schuricht; B Hamprecht
Journal:  Eur J Pharmacol       Date:  1985-04-23       Impact factor: 4.432

Review 3.  Prostaglandin receptors in the cardiovascular system: potential selectivity from receptor subtypes or modified responsiveness.

Authors:  M Keen; E Kelly; J MacDermot
Journal:  Eicosanoids       Date:  1989

4.  Endothelial cell adenylate cyclase: activation by catecholamines and prostaglandin I2+.

Authors:  A I Schafer; M A Gimbrone; R I Handin
Journal:  Biochem Biophys Res Commun       Date:  1980-10-31       Impact factor: 3.575

5.  cAMP attenuates autacoid release from endothelial cells: relation to internal calcium.

Authors:  A Lückhoff; A Mülsch; R Busse
Journal:  Am J Physiol       Date:  1990-04

6.  The stable prostacyclin analog, iloprost, and prostaglandin E1 inhibit monocyte procoagulant activity in vitro.

Authors:  D J Crutchley; M J Hirsh
Journal:  Blood       Date:  1991-07-15       Impact factor: 22.113

7.  Regulation of endothelial cell cyclic nucleotide metabolism by prostacyclin.

Authors:  N K Hopkins; R R Gorman
Journal:  J Clin Invest       Date:  1981-02       Impact factor: 14.808

8.  Blood-vessel wall arachidonate metabolism and its pharmacological modification in a new in vitro assay system.

Authors:  K Schrör; H Seidel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-02       Impact factor: 3.000

9.  Nitric oxide but not prostacyclin is an autocrine endothelial mediator.

Authors:  H Schröder; H Strobach; K Schrör
Journal:  Biochem Pharmacol       Date:  1992-02-04       Impact factor: 5.858

10.  Different sensitivities of prostaglandin-cyclooxygenases in blood platelets and coronary arteries against non-steroidal antiinflammatory drugs.

Authors:  K Schrör; S Sauerland; A Kuhn; R Rösen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-08       Impact factor: 3.000

View more
  4 in total

1.  Regulation of prostacyclin and prostaglandin E(2) receptor mediated responses in adult rat dorsal root ganglion cells, in vitro.

Authors:  D K Rowlands; C Kao; H Wise
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro.

Authors:  A A Weber; S Reimann; K Schrör
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

3.  S35b, a new phenylsulfonylfuroxan compound, inhibits thrombin-induced synthesis of platelet-activating factor and prostacyclin in human endothelial cells.

Authors:  R Heller; F Bussolino; R Calvino; D Ghigo; P Alessio; R Todde; R Fruttero; G Pescarmona; A Gasco; U Till
Journal:  Agents Actions       Date:  1993-11

4.  Synthesis of hyaluronan in oesophageal cancer cells is uncoupled from the prostaglandin-cAMP pathway.

Authors:  S Twarock; K Röck; M Sarbia; A A Weber; R U Jänicke; J W Fischer
Journal:  Br J Pharmacol       Date:  2009-03-26       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.